Apogee Therapeutics (NASDAQ:APGE) outlined new 52-week maintenance data from its Phase II APECS Part A study of zumilokibart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results